186 related articles for article (PubMed ID: 6155501)
1. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
2. Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism.
Gustafson A; Persson B; Tisell LE; Wiklund O; Ohlson R
Invest Urol; 1977 Nov; 15(3):220-4. PubMed ID: 591268
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract][Full Text] [Related]
4. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
5. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer].
Asakawa M; Wada S; Hayahara N; Yayumoto R; Kishimoto T; Maekawa M; Morikawa Y; Kawakita J; Umeda M; Horii A
Hinyokika Kiyo; 1990 Nov; 36(11):1361-9. PubMed ID: 2288316
[TBL] [Abstract][Full Text] [Related]
7. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
8. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
[TBL] [Abstract][Full Text] [Related]
9. Uptake in vivo of 45Ca in male accessory sex organs of the rat: effect of estramustine phosphate and diethylstilbestrol diphosphate.
Batra S; Müntzing J
Eur J Pharmacol; 1981 Nov; 76(1):87-91. PubMed ID: 7318924
[TBL] [Abstract][Full Text] [Related]
10. [The phase IV studies with Estracyt in prostatic cancer].
Ohhori T; Kubo T; Akasaka T; Funyu T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
Hinyokika Kiyo; 1988 Aug; 34(8):1493-502. PubMed ID: 3057833
[TBL] [Abstract][Full Text] [Related]
11. Estramustine phosphate (Estracyt): experimental and clinical studies in Europe.
Hoisaeter PA; Bakke A
Semin Oncol; 1983 Sep; 10(3 Suppl 3):27-33. PubMed ID: 6364363
[No Abstract] [Full Text] [Related]
12. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
Rambausek M; Lutherer S; Terhorst B
Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of stage D prostate cancer patients with hormones in combination with cyclophosphamide].
Fujii A; Yasuno H; Kawaida T; Nakamura I
Hinyokika Kiyo; 1986 Nov; 32(11):1713-7. PubMed ID: 2435128
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
Murase T; Mitsuya H; Honda N; Fukatu H; Aota Y; Shinoda M; Yoshida K; Sobajima T; Ohishi M; Tsumura Y
Hinyokika Kiyo; 1989 Jan; 35(1):179-85. PubMed ID: 2729015
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
Hedlund PO; Gustafson H; Sjögren S
Scand J Urol Nephrol Suppl; 1980; 55():103-5. PubMed ID: 6938012
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
Akaza H; Isurugi K; Oishi Y; Kitajima K; Sawamura Y; Baba S; Yoshida K; Otani M; Harada M; Gunji A
Jpn J Clin Oncol; 1988 Dec; 18(4):343-55. PubMed ID: 2462651
[TBL] [Abstract][Full Text] [Related]
17. [The phase IV studies with Estracyt in prostatic cancer--supplementary report: results of long-term therapy].
Ohhori T; Kubo T; Kawamura S; Suzuki T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
Hinyokika Kiyo; 1992 Aug; 38(8):979-87. PubMed ID: 1414749
[TBL] [Abstract][Full Text] [Related]
18. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
Toulouse J; Jung JL; Bittard M
J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of 3H-thymidine and 14C-amino acids into the ventral prostate after in vivo treatment with estradiol-3N-BIS(2-chloroethyl)carbamate-17 beta-phosphate (Estracyt) and its estrogen and cytostatic parts.
Hoisaeter PA
Invest Urol; 1976 Sep; 14(2):85-92. PubMed ID: 972011
[TBL] [Abstract][Full Text] [Related]
20. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
Daponte D; Sylvester R; De Pauw M; Fryszman A; Smith RM; Smith PH
Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
